Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth
Equity
Direct
Sector - Healthcare
NAV as on 23-12-2024
₹ 34.05
1D
Inception Returns
25.1%
/yr
About Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is an equity fund. This fund was started on 11 July, 2019. The fund is managed by Dhaval Shah. The fund could potentially beat inflation in the long-run.
Key Parameters
- Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth has ₹882 Cr worth of assets under management (AUM) as on Nov 2024 and is less than category average.
- The fund has an expense ratio 0.9.
Returns
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth has given a CAGR return of 25.08% since inception. Over the last 1, 3 and 5 years the fund has given a CAGR return of 39.47%, 21.29% and 26.17% respectively.
Holdings
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth has allocated its funds majorly in Cash Equivalent, Health, Basic Materials. Its top holdings are Sun Pharmaceuticals Industries Ltd, Cipla Ltd, Torrent Pharmaceuticals Ltd, Apollo Hospitals Enterprise Ltd, Fortis Healthcare Ltd
Taxation
As it is a sector - healthcare mutual fund the taxation is as follows:For short term (less than a year) capital gains will be taxed at 15%For long term (more than 1 year) capital gains will be taxed at 10% without indexation benefitDividends will always be taxed at slab rate. Gains upto Rs 1 lakh are exempt in case of long term.
Investment objective of Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth
The scheme provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India. The Scheme does not guarantee/indicate any returns. There can be no assurance that the schemes’ objectives will be achieved.
Minimum Investment and lockin period
Minimum investment for lump sum payment is INR 1000.00 and for SIP is INR 100.00. Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth has no lock in period.
Historical NAV & Returns
Annualised
▲
▼
1067 people have invested ₹ 1.1Cr in Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth in the last three months
INDmoney Rank for Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth
Powered by IND quant engine
IND ranking is not available for this fund.
Beats FD returns for both 3Y & 5Y duration
5Y returns in the bottom 25% of the category
3Y returns in the bottom 25% of the category
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Overview
| Expense ratio | 0.93% |
Benchmark | S&P BSE Healthcare PR |
| AUM | ₹882 Cr |
| Inception Date | 11 July, 2019 |
| Min Lumpsum/SIP | ₹1000/₹100 |
Exit Load | 1.0% |
| Lock In | No Lock-in |
TurnOver | 33.35% |
| STCG | Selling mutual fund before 1 year, returns taxed at 20%. |
| LTCG | After 1 year, 12.5% tax on returns over ₹1.25 lakh/year. |
| Risk |   Very High Risk |
Trailing Returns
as on (23-Dec-24)
Fund Distribution
as on (30-Nov-24)
Large cap
43.6%
Mid cap
31.8%
Small cap
18.1%
Sector Allocation
Health
99.1%
Basic Materials
0.9%
All changes are between Sep'24 and Nov'24
- This fund’s returns stands at -1.81% whereas the fund’s underlying benchmark Nifty 500 returns stands at -0.60% as on Nov'24
- This fund underperformed Nifty 500 by 1.21% in Nov'24
- AUM of the fund stands at 881.5 Cr as of Nov'24
- AUM has remained same between Nov'24 and Oct'24
Top Stocks bought last month
Torrent Pharmaceuticals Ltd's allocation increased from 7.07% to 8.35%
Lupin Ltd's allocation increased from 4.07% to 4.71%
Vijaya Diagnostic Centre Ltd's allocation increased from 2.5% to 3.02%
Top Stocks sold last month
Sun Pharmaceuticals Industries Ltd's allocation decreased from 14.39 % to 14.31 %
Aurobindo Pharma Ltd's allocation decreased from 5.41 % to 5.04 %
Ipca Laboratories Ltd's allocation decreased from 5.26 % to 3.98 %
Mid Cap allocation has gone down from 32.2% to 31.8%
Large Cap allocation has gone up from 42.1% to 43.6%
Small Cap allocation has gone up from 16.2% to 18.1%
Cash allocation has gone down from 6.4% to 2.2%
Top 3 Sectors in November were Health, Financial Services & Basic Materials
Nov'24
Health
99%
Basic Materials
Oct'24
Health
98%
Financial Services
1%
Basic Materials
See all
Top Growth Drivers | 1M Return |
|---|---|
 Torrent Pharmaceuticals Ltd | 11.8% |
 Jupiter Life Line Hospitals Ltd | 1.9% |
Loading...
We are taking more time than usual
Dhaval Shah
Fund Manager of Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth, since 11 July 2019
Top funds managed
Fund House
Aditya Birla Sun Life AMC Ltd
Total Schemes
Total AUM
₹3.78L Cr
as on 29-Nov-2024
Address
Aditya Birla Sun Life AMC Ltd,One World Centre, Tower 1, 17th Floor,Jupiter Mill Compound, 841, Senapati Bapat Marg,Elphinstone Road
Phone
+912243568000
Website
connect@birlasunlife.com
Mutual Fund Insights
This fund has one of the lowest expense ratio in the category (sector - healthcare). Its expense ratio is 0.92% which is lower than the category average expense ratio of 1.39%.
In the last 3 years, ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth has given 27% return, outperforming this fund by 5.71% per annum.
In the last 1 year, HDFC Pharma and Healthcare Fund Direct Growth has given 53.85% return, outperforming this fund by 14.37%.
Over the last 6 months, this fund has experienced a 29.0% growth in AUM moving from 683.18 Cr to 881.52 Cr.
In the last 5 years, DSP Healthcare Fund Direct Growth has given 32.66% return, outperforming this fund by 6.49% per annum.
Over the last 1 year, this fund has decreased expense ratio by 16.4% moving from 1.10 to 0.92.
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Highlights
Very High Risk
Investors understand that their principal will be at Very High Risk
About the fund
This fund has delivered an average annual returns of 25.08% since inception which is more than its category average return of 24.33%
Fund Allocations
This fund has an allocation of 97.82% in Equity, 0% in Debt and 2.18% in Cash related instruments
AUM size ₹882 Cr
This fund has AUM of ₹882 Cr which is less than its category average of ₹ 1857 Cr
Expense Ratio 0.93%
This fund has an expense ratio of 0.93% which is less than its category average expense ratio of 1.22%
Frequently Asked Questions for Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth
The current NAV of Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is ₹34.05 as on 23-Dec-2024.
Existing (Absolute + CAGR) as on 23-Dec-2024.
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth | Absolute Returns | CAGR Returns |
1 Month Returns | 3.82% | 3.82% |
6 Month Returns | 15.53% | 15.53% |
1 Year Returns | 39.47% | 39.47% |
3 Years Returns | 78.43% | 21.29% |
5 Years Returns | 219.76% | 26.17% |
With INDmoney, the process of investing is very simple and involves zero commission.
- Click Buy on the fund name.
- Input the amount you are looking to invest.
- Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
- Select your bank account and proceed with Payment.
0.93% as on November 2024
₹882 Cr as on November 2024
Sun Pharmaceuticals Industries Ltd(14.31%), Cipla Ltd(9.01%), Torrent Pharmaceuticals Ltd(8.35%), Apollo Hospitals Enterprise Ltd(5.91%), Fortis Healthcare Ltd(5.61%) as on November 2024
The alpha ratio for the Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Alpha 1 Year | Alpha 3 Years | Alpha 5 Years |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth | -7.22 | -0.75 | 0.27 |
As on November 2024
The alpha for Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Beta 1 Year | Beta 3 Years | Beta 5 Years |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth | 1.08 | 0.98 | 0.92 |
As on November 2024
The Beta for Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Sharpe Ratio 1 Year | Sharpe Ratio 3 Years | Sharpe Ratio 5 Years |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth | 1.84 | 0.8 | 1.05 |
As on November 2024
The sharpe ratio for Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Standard Deviation 1 Year | Standard Deviation 3 Years | Standard Deviation 5 Years |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth | 14.47 | 16.07 | 18.49 |
As on November 2024
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Sortino ratio is 1.49 as on November 2024. Sortino ratio tells the downside risk-adjusted-returns of the mutual fund.
Dhaval Shah is the fund manager of Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth
The Exit load of Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is 1%